22.418 articles found

Frontiers in the surgical treatment of Parkinson's disease.

Remple MS, Sarpong Y, Neimat JS.

Expert Rev Neurother · 2008-06-01

DOI: 10.1586/14737175.8.6.897PMID: 18505355

Working memory in Parkinson's disease patients: clinical features and response to levodopa.

Beato R, Levy R, Pillon B, Vidal C, du Montcel ST, Deweer B, Bonnet AM, Houeto JL, Dubois B, Cardoso F.

Arq Neuropsiquiatr · 2008-06-01

DOI: 10.1590/s0004-282x2008000200001PMID: 18545772

Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's disease.

Bagh MB, Maiti AK, Jana S, Banerjee K, Roy A, Chakrabarti S.

Free Radic Res · 2008-06-01

DOI: 10.1080/10715760802158430PMID: 18569015

Bitemporal electroconvulsive therapy for depression in a Parkinson disease patient with a deep-brain stimulator.

Bailine S, Kremen N, Kohen I, Linder H, Schwartz GJ, Mogilner AY, Pourfar M.

J ECT · 2008-06-01

DOI: 10.1097/yct.0b013e318154b993PMID: 18580566

Therapeutic strategy of erythropoietin in neurological disorders.

Liu XB, Wang JA, Yu SP, Keogh CL, Wei L.

CNS Neurol Disord Drug Targets · 2008-06-01

DOI: 10.2174/187152708784936617PMID: 18673207

Calpain as a potential therapeutic target in Parkinson's disease.

Samantaray S, Ray SK, Banik NL.

CNS Neurol Disord Drug Targets · 2008-06-01

DOI: 10.2174/187152708784936680PMID: 18673214

[Patterns of neuronal activity in the basal ganglia nucleus in parkinsonian patients with levodopa-induced dyskinesia].

Li XY, Zhuang P, Li YJ.

Zhonghua Yi Xue Za Zhi · 2008-06-01

PMID: 19035099

A THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES

SUGIYAMA SATORU, MIKI TOKUTARO, NISHIKAWA HIROSHI.

· 2008-05-30

A FILAMENTOUS AGGREGATES OF HUMAN DJ-1 PROTEIN AND SCREENING METHODS FOR TREATMENT OF PARKINSON'S DISEASE USING IT

CHA SUN SHIN, JEONG CHANG SOOK, AN YOUNG JUN, JEONG HA IL.

· 2008-05-30

Levodopa reduces risk factors for vascular disease in parkinsonian patients.

Scigliano G, Ronchetti G, Girotti F, Musicco M.

J Neurol · 2008-05-30

DOI: 10.1007/s00415-008-0869-8PMID: 18500492

Compounds for the Treatment of Neurodegeneration and Stroke

HERGENROTHER PAUL J, PUTT KARSON S, LIU XIANJUN.

· 2008-05-29

Tongue point encephalopathy therapy apparatus

JIEGUANG SUN, XUERAN SUN.

· 2008-05-28